Drs. Joe Neglia and Christopher Moertel named Magazine's Top Doctors
Two physicians conducting research supported by Children’s Cancer Research Fund receive high honor.
In a random poll of 2,500 local doctors and 2,500 nurses, Drs. Neglia and Moertel were in the top 15% of vote recipients in the field of pediatric hematology and oncology in a recent poll conducted by Mpls/St.Paul Magazine.
Dr. Joe Neglia
Dr. Neglia serves on Children's Cancer Research Fund Board of Directors as a Medical Advisor. He is a Professor in the Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation at the University of Minnesota in Minneapolis and Section Chief of Pediatric Hematology/Oncology.
Dr. Neglia has been at the University of Minnesota since 1984 when he came to pursue a fellowship in Pediatric Hematology/Oncology and Blood and Marrow Transplantation.
Areas of research for Dr. Neglia include long-term effects of cancer therapy in cancer survivors and the occurrence of second malignancies following childhood cancer. He is nationally and internationally recognized for his contributions to the field of childhood cancer long-term effects. He is also adored and admired by his patients and colleagues.
Dr. Chris Moertel
Dr. Moertel was recently named director of a new brain tumor program at University of Minnesota Children's Hospital, Fairview. This program is the result of the collaborative effort by the Department of Pediatrics, the University of Minnesota Physicians, Fairview, and the Children's Cancer Research Fund. Moertel is a professor in the University of Minnesota Medical School's Department of Pediatrics, Division of Hematology/Oncology.
The Pediatric Neuro-Oncology Program is the first comprehensive research and treatment program in the Midwest and one of few such programs in the United States. Its purpose is twofold: conduct leading edge research on pediatric brain and spinal cord cancers and provide the most advanced treatment for children diagnosed with these conditions.
Dr. Moertel specializes in research and treatment of pediatric brain tumors, rare pediatric tumors, neurofibromatosis-associated neoplasia and therapy of children with brain and spinal cord tumors. Moertel has been named a Mpls/St.Paul Magazine Top Doc in at least four of the last six surveys.
Children's Cancer Research Fund extends its congratulations to Drs. Neglia and Moertel for their deserving receipt of this honor.